Table 3.
Observational studies included in the final analysis.
| Author | Year | Country | N = 290 | Malignancy | Age | Liver biopsy | Platelets (n°/mm3) | Total bilirubin (mg/dl) | Albumin (g/dl) | Chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Oliai et al.1 | 2019 | US | 37 | Breast |
49.3 SD 13.5 |
n.a. | n.a. |
6 SD 6.7 |
2.7 SD 0.7 |
37/37 (100%) |
| Qayyum et al.21 | 2007 | US | 68 | Breast | n.a. | n.a. | n.a. | n.a. | n.a. | 68/68 (100%) |
| Fennessy et al.19 | 2004 | Switzerland | 29 | Breast | n.a. | n.a. | n.a. | n.a. | n.a. | 29/29 (100%) |
| Young et al.7 | 1994 | US | 22 | Breast | 48 | nodular regenerative hyperplasia; breast cancer cells | n.a. | n.a. | n.a. | 22/22 (100%) |
| Gopalakrishnan et al.20 | 2018 | US | 86 | Breast | 57.5 (range 32.4–82.4) | n.a. |
Median 195.000 IQR 137.000–217.000 |
Median 0.5 IQR 0.3–0.9 |
Median 3.6 IQR 3.2–4 |
86/86 (100%) |
| Engelman et al.12 | 2020 | Belgium | 48 | Breast |
50.6 SD 11.6 |
n.a. |
187.000 SD 82.7 |
1 SD 1 |
3.5 SD 0.8 |
48/48 (100%) |